Incyte (INCY) vs. Celator Pharmaceuticals (CPXX) Head to Head Review

Incyte (NASDAQ: INCY) and Celator Pharmaceuticals (NASDAQ:CPXX) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, institutional ownership, valuation, profitability and risk.

Institutional and Insider Ownership

90.7% of Incyte shares are held by institutional investors. 17.7% of Incyte shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Incyte and Celator Pharmaceuticals, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Incyte 0 5 18 0 2.78
Celator Pharmaceuticals 0 0 0 0 N/A

Incyte currently has a consensus target price of $142.86, indicating a potential upside of 53.51%. Given Incyte’s higher probable upside, equities analysts clearly believe Incyte is more favorable than Celator Pharmaceuticals.

Valuation and Earnings

This table compares Incyte and Celator Pharmaceuticals’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Incyte $1.11 billion 17.76 $104.22 million ($0.80) -116.33
Celator Pharmaceuticals N/A N/A N/A ($0.59) -51.25

Incyte has higher revenue and earnings than Celator Pharmaceuticals. Incyte is trading at a lower price-to-earnings ratio than Celator Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.


This table compares Incyte and Celator Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Incyte -10.90% -12.91% -7.41%
Celator Pharmaceuticals N/A -75.03% -46.70%


Incyte beats Celator Pharmaceuticals on 7 of the 10 factors compared between the two stocks.

Incyte Company Profile

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib). JAKAFI (ruxolitinib) is indicated for the treatment of patients with intermediate or high risk myelofibrosis (MF) and for the treatment of patients with polycythemia vera (PV) having had an inadequate response to or are intolerant of hydroxyurea. As of December 31, 2016, the Food and Drug Administration had granted JAKAFI orphan drug status for MF, PV and essential thrombocythemia. The primary target for ICLUSIG is B Cell Receptor-ABL, an abnormal tyrosine kinase that is expressed in chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. The Company also has a portfolio of selective janus associated kinases 1 (JAK1) inhibitors.

Celator Pharmaceuticals Company Profile

Celator Pharmaceuticals, Inc. is an oncology-focused biopharmaceutical company. The Company is engaged in developing products to improve patient outcomes in cancer. The Company’s technology platform, CombiPlex, enables the design and evaluation of optimized combinations incorporating traditional chemotherapies, as well as molecularly targeted agents to deliver anti-cancer activity. The Company’s product, VYXEOS, a nano-scale liposomal formulation of cytarabine:daunorubicin, in Phase III clinical testing for the treatment of acute myeloid leukemia. The Company also conducted clinical development efforts on CPX-1, a nano-scale liposomal formulation of irinotecan:floxuridine for the treatment of colorectal cancer; and has a preclinical stage product candidate CPX-8, a hydrophobic docetaxel prodrug nanoparticle formulation. The Company operates in the United States and Canada.

Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with's FREE daily email newsletter.

Leave a Reply